文献速递白血病淋巴瘤

泽布替尼治疗初治及复发/难治性慢性淋巴细胞白血病的长期随访:I/II期AU-003研究

Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study.
PubMed 文献 · Br J Haematol · 2021-12-16

I/II期AU-003研究纳入123例初治或复发/难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者,中位随访47.2个月,泽布替尼总体缓解率95.9%(初治100%,复发/难治95%),完全缓解率18.7%,3年持续缓解率85.7%,长期耐受性持续。

要点

  • 泽布替尼总体缓解率95.9%,初治患者100%,复发/难治患者95%。
  • del(17p)/TP53突变患者总体缓解率87.5%,完全缓解率16.7%。
  • 2年无进展生存率90%,3年无进展生存率83%,房颤等年发生率随时间下降。

核心结论

  • 中位随访约4年,泽布替尼治疗的缓解仍具有临床意义且持久,长期耐受性持续。

研究设计与样本

  • I/II期AU-003研究,纳入123例初治或复发/难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者,中位随访47.2个月。

主要发现

  • 总体缓解率95.9%(初治100%,复发/难治95%),完全缓解率18.7%,3年时持续缓解率85.7%。
  • del(17p)/TP53突变患者总体缓解率87.5%,完全缓解率16.7%。
  • 2年无进展生存率90%(初治90%,复发/难治91%),3年无进展生存率83%(初治81%,复发/难治83%)。
  • 最常见的≥3级不良事件为中性粒细胞减少(15.4%)、肺炎(9.8%)、高血压(8.9%)和贫血(6.5%)。
  • 房颤、大出血、≥3级中性粒细胞减少和≥3级感染的年度发生率随时间下降。

关键数值与推荐

  • 泽布替尼给药方案:160 mg每日两次(81例)、320 mg每日一次(40例)或160 mg每日一次(2例)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The phase I/II AU-003 study in patients with treatment-naïve (TN) or relapsed/refractory (R/R) chronic lymphocytic leukaemia/small lymphocytic lymphoma demonstrated that zanubrutinib therapy results in clinically meaningful and durable responses with acceptable safety and tolerability. We report updated safety and efficacy data for 123 patients with a median follow-up of 47·2 months. Patients received zanubrutinib 160 mg twice daily (81 patients), 320 mg once daily (40), or 160 mg once daily (two). Discontinuations due to adverse events or disease progression were uncommon. The overall response rate (ORR) was 95·9% (TN, 100%; R/R, 95%) with 18·7% achieving complete response (CR). Ongoing response at 3 years was reported in 85·7%. The ORR in patients with del(17p)/tumour protein p53 mutation was 87·5% (CR 16·7%). The 2- and 3-year progression-free survival estimates were 90% (TN, 90%; R/R, 91%) and 83% (TN, 81%; R/R, 83%) respectively. The most reported Grade ≥3 adverse events were neutropenia (15·4%), pneumonia (9·8%), hypertension (8·9%) and anaemia (6·5%). The annual incidence of atrial fibrillation, major haemorrhage, Grade ≥3 neutropenia and Grade ≥3 infection decreased over time. With a median follow-up of ~4 years, responses remain clinically meaningful and durable and long-term tolerability to zanubrutinib therapy continues.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Cull G, Burger JA, Opat S, et al. Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study. Br J Haematol. 2021. PMID: 34915592. doi:10.1111/bjh.17994

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。